Pregled bibliografske jedinice broj: 147856
Atopic dermatitis - What's new in therapy?
Atopic dermatitis - What's new in therapy? // Journal of the European Academy of Dermatology and Venereology / Ortonne, Jean-Paul (ur.).
Brisel: Blackwell Publishing, 2004. (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 147856 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Atopic dermatitis - What's new in therapy?
Autori
Lipozenčić, Jasna ; Murat Sušić, Slobodna
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Journal of the European Academy of Dermatology and Venereology
/ Ortonne, Jean-Paul - Brisel : Blackwell Publishing, 2004
Skup
Second EADV International Spring Symposium
Mjesto i datum
Budimpešta, Mađarska, 29.04.2004. - 01.05.2004
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Atopic dermatitis; topical corticosteroids; cyclosporine; systemic immunosuppressive treatment; UVA-UVB; narrow band UVB; UVA1 PUVA
Sažetak
Atopic dermatitis is a common, chronic inflammatory skin disease. Treatment is still symptomatic, mainly aimed at reduction of skin inflammation and decrease of itch. General management includes avoidance of specific irritans and allergens and adequate skin care. Antihistamines, especially those with sedating effect, have some benefits on pruritus, at least in some patients. Topical corticosteroids (CD) remain still the first line of treatment in AD patients. Treatment of secondary bacterial infections, fungal and viral skin infections should be appropriately addressed as well. Topical calcineurin inhibitors, tacrolimus and pimecrolimus, represent new treatment optpion for AD patients. They have a strong antiinflammatory sctivity, high safety profile and can be applicated even on delicate skin areas. For patients with severe and refractory disease phototherapy with UVA-UVB, narrow band UVB, UVA1 or PUVA can be the treatment of choice. Systemic immunosuppressive therapy requires close monitoring because of their potential toxicity. Refractory cases of AD have been treated with intravenous immunoglobulins and interferon gama. Immunotherapy with aeroallergens has not been proven effective in AD patients. It may be effective in patients with an unequivocal history of aeroallergen induced atopic dermatitis. Phosphodiesterase inhibitors and leukotriene antagonists in the future may prove to be beneficial in the treatment of AD.
Izvorni jezik
Engleski
Znanstvena područja
Elektrotehnika
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb